Sacha Ninkovic

USPTO Granted Patents = 23 (Patent Applications = 9)

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 8.2

ph-index = 8

Forward Citations = 197(Granted Patents)

Location History:

Carlsbad, CA (US) (2005 - 2008)
La Jolla, CA (US) (2013 - 2022)
San Diego, CA (US) (2002 - 2023)

Company Filing History:

The Scripps Research Institute

patents

3 out of 174

Agouron Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378232 - Cyclin dependent kinase inhibitors (2025-08-05),

2. 11773082 - CDK2 inhibitors (2023-10-03),

3. 11718603 - CDK2 inhibitors (2023-08-08),

4. 11396512 - CDK2/4/6 inhibitors (2022-07-26),

5. 11220494 - Cyclin dependent kinase inhibitors (2022-01-11),

6. 11014911 - CDK2 inhibitors (2021-05-25),

7. 10800783 - CDK2/4/6 inhibitors (2020-10-13),

8. 10766884 - Cyclin dependent kinase inhibitors (2020-09-08),

9. 10544095 - 3-indol substituted derivatives, pharmaceutical compositions and methods for use (2020-01-28),

10. 10246433 - Aryl and heteroaryl fused lactams (2019-04-02),

11. 10233188 - CDK2/4/6 inhibitors (2019-03-19),

12. 9873690 - 3-indol substituted derivatives, pharmaceutical compositions and methods for use (2018-01-23),

13. 9593097 - Axl inhibitors (2017-03-14),

14. 9328096 - Tropomyosin-related kinase inhibitors (2016-05-03),

15. 9040515 - Aryl and heteroaryl fused lactams (2015-05-26),

Title: The Innovations of Sacha Ninkovic in Pharmaceutical Development

Introduction: Sacha Ninkovic, located in La Jolla, California, is a distinguished inventor known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 22 patents, Ninkovic's work primarily focuses on advanced therapeutic compounds that target abnormal cell growth, including various forms of cancer.

Latest Patents: Among his latest inventions are innovative CDK2 inhibitors. These inventions pertain to compounds of Formula (I) and their enantiomers, along with pharmaceutically acceptable salts. This technology plays a crucial role in the development of pharmaceutical compositions aimed at treating cancer in subjects suffering from abnormal cell growth. The applications of these compounds extend to various therapeutic methods designed to combat serious health conditions.

Career Highlights: Ninkovic has built a noteworthy career through his collaborations with leading organizations in the pharmaceutical industry. His experience at Pfizer Corporation provided him with invaluable insights and opportunities to develop cutting-edge treatments. Additionally, his time at The Scripps Research Institute allowed him to engage in pioneering research that has further propelled his inventive innovations.

Collaborations: Throughout his career, Ninkovic has worked alongside talented individuals like Asako Nagata and Eugene Yuanjin Rui. These collaborations have not only enriched his research but have also contributed to the platform for ongoing advancements in cancer treatments and pharmaceutical development.

Conclusion: Sacha Ninkovic exemplifies the spirit of innovation in the pharmaceutical sector. His focused efforts on developing CDK2 inhibitors and other compounds showcase his commitment to finding effective solutions for cancer treatment. With a solid foundation in collaboration and research, Ninkovic continues to lead the way in the fight against disease through his inventive contributions.

This text is generated by artificial intelligence and may not be accurate.